novo nordisk semaglutide clinical trials Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug Novo Nordisk said on Tuesday

Cancer Res 85 , 1585 (2025)

GLP-1 receptor agonists are a powerful class of drugs that help lower blood sugar, support weight loss, and even protect against heart disease in people with type 2 diabetes

7.4.4 Next-generation agonists The development of dual GLP-1/GIP receptor agonists (e.g., tirzepatide) and novel blood-brain barrier-penetrant formulations may offer superior neuroprotective efficacy by more potently engaging central receptors or providing a broader spectrum of action (Ghaleb et al., 2025)

Ultimate Sun Protection: Protect your skin daily with this non-greasy, broad-spectrum SPF 50 sunscreen

The patients who fare best are those who reach out early to their care team for help, Saunders says

Adverse reactions to drugs